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Introduction {#sec1}
============

Messenger RNA processing (5′ capping, splicing, and 3′ end processing) is a fundamental step in eukaryotic gene expression to sustain various cell functions, such as proliferation, survival, and differentiation ([@bib30], [@bib32], [@bib34]). Among them, mRNA splicing is a crucial process through which noncoding introns are removed from pre-mRNA by the spliceosome, composed of five snRNPs (small nuclear ribonucleoproteins: U1, U2, U4, U5, and U6 snRNPs) and an assembly of accessory proteins ([@bib17], [@bib46]). This machinery recognizes short consensus sequences in the pre-mRNA, at the 5′ splice site, the branchpoint sequence (BPS), and the 3′ splice site. Alternative splicing plays an important role in conferring remarkable variety on the eukaryotic transcriptome through the differential usage of splice sites ([@bib21], [@bib35], [@bib47]). It has been suggested that abnormalities in mRNA splicing lead to many pathological conditions, such as cancer onset and progression ([@bib41], [@bib52]). For this reason, the inhibition of inadequate splicing is attracting attention as an important therapeutic strategy ([@bib5], [@bib14], [@bib29], [@bib33], [@bib40]).

Various studies to detect compounds with inhibitory activity on splicing have been performed, and these successfully identified several microorganism-derived compounds with activities that modulate mRNA splicing ([@bib8]). For example, spliceostatin A, pladienolide B, GEX1A, and H3B-8800 inhibit pre-mRNA splicing by disturbing spliceosome complex formation via binding to a component of the SF3B complex, one of the constituents of U2 snRNP ([@bib15], [@bib20], [@bib22], [@bib42]).

Regarding food-derived compounds, epigallocatechin gallate, apigenin, and resveratrol were first identified by their inhibitory effects on the growth of cancer cells and later revealed to induce the alternative splicing of several mRNAs ([@bib1], [@bib31], [@bib39]). However, only a few reports to date have been published on food-derived compounds with the ability to modulate mRNA processing. Because various previous studies have focused on compounds with strong inhibitory effects on splicing, the compounds with relatively moderate activity, such as food-derived compounds, have been overlooked.

In our established method, a relatively moderate inhibitory effect on mRNA processing can be captured as bulk poly(A)^+^ RNA accumulation in the nucleus ([@bib11], [@bib12]). Utilizing our method, we previously screened food-derived compounds and identified mRNA processing inhibition activities in the soybean-derived isoflavonoid fraction and performed further analysis that elucidated that this activity was mainly exerted by compounds with a flavone skeleton ([@bib23], [@bib24]).

In this study, we assessed the activity of 21 compounds with a flavone skeleton to inhibit mRNA processing and found that two of these flavonoids with highly related structures, namely, apigenin and luteolin, exhibited the strongest activity. LC-MS/MS analysis of proteins bound to these compounds suggested that their cellular targets are mRNA splicing-related proteins. RNA-seq data revealed that many alternative splicing events were induced upon treatment with these flavonoids, strongly suggesting the effect of these compounds on mRNA splicing. Further extensive analysis of the sequence features of target introns indicated that these flavonoids tend to influence the splicing of introns with weak splice sites.

This study provides an effective approach to identify compounds exerting moderate inhibitory activity against mRNA processing, with a particular emphasis on the usefulness of global analysis to clarify the mechanisms underlying the perturbations induced by these compounds in mRNA processing. Using the method described in this study, previously overlooked chemical libraries, such as those of food-derived compounds, are worth revisiting as potential sources of compounds with moderate activity of modulating mRNA processing.

Results {#sec2}
=======

Apigenin and Luteolin Exhibit Inhibitory Activity against mRNA Processing {#sec2.1}
-------------------------------------------------------------------------

Previously, we identified several flavonoids that have inhibitory activity against mRNA processing ([@bib23], [@bib24]). In this study, we explored the structure-activity relationship of compounds with a flavone skeleton by RNA-FISH ([Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}). GEX1A, a well-known splicing inhibitor, was used as a positive control. The structure of flavones contains a skeleton of diphenylpropane, namely, two benzene rings (A-ring and B-ring) linked via a closed pyran ring (C-ring) with a benzenic A-ring. In addition, they have a double bond between the 2 and 3 positions and a ketone at the 4 position of the C-ring. Among the 21 compounds tested, apigenin and luteolin exhibited the most intense and dose-dependent phenotype of accumulating poly(A)^+^ RNA in the nucleus ([Figures 2](#fig2){ref-type="fig"}A--2C). These compounds harbor OH groups at the 5 and 7 positions of the A-ring, an OH group at the 4′ position of the B-ring, and a double bond in the C-ring as common structures, whereas an OH group at the 6 position of the A-ring, or the 2′ or 5′ position of the B-ring, appears to eliminate the flavonoids\' activity on mRNA processing ([Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}B). In apigenin- and luteolin-treated cells, poly(A)^+^ RNAs mainly co-localized with SC35, a nuclear speckle marker protein, indicating the accumulation of RNAs residing within the nuclear speckles ([Figure 2](#fig2){ref-type="fig"}D). This phenomenon was also observed in cells treated with GEX1A.Figure 1Activity of Compounds with Flavone Skeleton Examined for mRNA Processing InhibitionSee also [Figure S1](#mmc1){ref-type="supplementary-material"}.Figure 2Inhibitory Activity against mRNA Processing of Apigenin and Luteolin(A) Chemical structures of apigenin and luteolin.(B) RNA-FISH was performed to determine the localization of bulk poly(A)^+^ RNA. U2OS cells were treated with the indicated concentrations of each compound for 24 h GEX1A (30 ng/mL) was used as a positive control. The bulk poly(A)^+^ RNA was visualized by Alexa Fluor 594-labeled oligo-dT~45~ probe. The nuclei were visualized with DAPI. Scale bar, 50 μm.(C) The ratio of the nuclear distribution of mRNA was analyzed. The signal intensities of the whole cell and the nucleus were quantified using ImageJ (n = 35). Boxes show median (center line) and upper and lower quartiles. Whiskers show the lowest and highest values. Statistical analysis was performed using one-way ANOVA followed by Dunnett\'s test. \*\*\*p \< 0.001.(D) The localization of bulk poly(A)^+^ RNA and nuclear speckles. Poly(A)^+^ RNA (red), speckles (green), and chromosomal DNA (blue) were visualized in U2OS cells for co-localization analysis. Cells were treated with each indicated compound for 24 h. Scale bar, 10 μm. In right panels, signal intensities of poly(A)^+^ RNA and SC35 were plotted between a and b lines in the left panels. Poly(A)^+^ RNA and SC35 signal are shown with red and green lines, respectively.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

mRNA Splicing Is a Candidate for the Cellular Target of Apigenin and Luteolin {#sec2.2}
-----------------------------------------------------------------------------

The observed nuclear poly(A)^+^ RNA accumulation in apigenin- and luteolin-treated cells may reflect the disruption of an mRNA export pathway ([@bib25]). To examine this possibility, we assessed the subcellular localization of transiently expressed *β-globin* mRNA in control cells and apigenin- or luteolin-treated cells. Expressed reporter *β-globin* mRNA was visualized using Alexa Fluor 546-labeled *β-globin* FISH probe ([Figures 3](#fig3){ref-type="fig"}A and 3B). Even in cells exhibiting a prominent phenotype of poly(A)^+^ RNA accumulation in the nucleus induced by treatment with these flavonoids, *β-globin* mRNA was exported to the cytoplasm as efficiently as in control cells, indicating that the general mRNA export machinery is not disturbed in these cells. In addition, the *β-globin* gene used in this assay contains introns with constitutive splice sites, suggesting that this reporter mRNA properly undergoes splicing. Indeed, when we assessed the splicing of this reporter mRNA, no obvious inhibition caused by these flavonoids was observed ([Figure 3](#fig3){ref-type="fig"}C). On the other hand, it has been reported that apigenin and luteolin treatment alters the splicing pattern of *Caspase-9* and *c-FLIP* into an apoptosis-inducible form, thus inhibiting the proliferation of cancer cells ([@bib1]). Those previously described changes in splicing pattern, namely, the decreases in both *Caspase-9b*, a variant with skipping of exons 3--6, and *c-FLIP*~*s*~, a variant with exon 7 instead of 8, were also induced by apigenin and luteolin treatment in our experimental conditions, implying that these flavonoids have some effect on splicing ([Figure 3](#fig3){ref-type="fig"}D). Supporting the idea that apigenin and luteolin affect splicing rather than export, the apigenin- and luteolin-derived nuclear speckle-associated poly(A)^+^ RNA accumulation pattern was similar to that observed in cells depleted of SF3B1, a component of U2 snRNP ([Figure S2](#mmc1){ref-type="supplementary-material"}A), and was distinguishable from the uniform poly(A)^+^ RNA accumulation throughout the nucleus observed in cells depleted of TAP (also known as NXF1), an mRNA exporter ([Figure S2](#mmc1){ref-type="supplementary-material"}B) ([@bib48]). The subnuclear localization of accumulated poly(A)^+^ RNA observed in apigenin- and luteolin-treated cells was also reminiscent of a phenotype exhibited by cells treated with spliceostatin A, a well-known splicing inhibitor, also implicating the mRNA splicing process as a cellular target of these flavonoids ([Figure 2](#fig2){ref-type="fig"}D) ([@bib3], [@bib20]).Figure 3The Effect on Splicing of Some Genes and Identification of Apigenin- and Luteolin-Targeted Proteins(A) Schematic of *β-globin* construct containing the CMV promoter and BGH poly(A) site is presented. Horizontal lines indicate introns, and boxes indicate exons.(B) The localization of *β-globin* mRNA was observed. Bulk poly(A)^+^ RNA (green), *β-globin* mRNA (red), and chromosomal DNA (blue) were visualized in U2OS cells. Scale bar, 10 μm.(C) The splicing pattern of *β-globin* gene was observed by RT-PCR using total RNA. The digit panel below the photo shows the percentage of unspliced mRNA band intensity and representative results of triplicate experiments. DNA size in base pairs (b.p.) is indicated on the left side. Control: marker for unspliced *β-globin* mRNA. RT: reverse transcription.(D) The change of splicing pattern of *Caspase-9* and *c-FLIP*. RT-PCR was performed using total RNA. DNA size in base pairs (b.p.) is indicated on the right side. The digit panels below the photo show the percentage of the indicated isoform and representative results of triplicate experiments.(E) Gene ontology analysis of proteins bound with apigenin or luteolin is shown. Proteins with protein score \>0 in [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"} were uploaded to the DAVID database for GO analysis.See also [Figures S2--S4](#mmc1){ref-type="supplementary-material"}.

To explore the way in which these flavonoids influence poly(A)^+^ RNA metabolism in human cells, proteins bound to apigenin and luteolin were analyzed. Flavonoid was fixed on magnetic FG beads with an epoxy linker and was incubated with nuclear extract from HEK293 cells. Purified proteins were analyzed by LC-MS/MS ([Figures 3](#fig3){ref-type="fig"}E, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). The interaction between some of the LC-MS/MS-detected proteins and either apigenin or luteolin was confirmed by the western blotting using specific antibodies against these proteins ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Gene ontology analysis demonstrated that many of the detected proteins have mRNA splicing-related functions ([Figure 3](#fig3){ref-type="fig"}E). Further detailed classification of the splicing-related proteins according to a previous report indicated that these compounds most intensely interact with U2 and U5 snRNP, components of the spliceosome ([Figure S3](#mmc1){ref-type="supplementary-material"}B) ([@bib16]). HNRNPA2B1, a protein that has been reported to interact with apigenin ([@bib1]), was also detected to a lesser extent than U2 and U5 snRNP components. To obtain insights into the interaction of apigenin and luteolin with their potential targets, docking studies were performed using the crystal structure of human SF3B1, a component of the SF3B subcomplex in the U2 snRNP, in a complex with E7107, a pladienolide derivative analog (PDB code: [5ZYA](pdb:5ZYA){#intref0010}) ([@bib10]). Our docking algorithm predicted that apigenin and luteolin are likely to bind to SF3B1 near the E7107-binding site ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Both flavonoids interact with several hydrophobic residues such as Leu1066, Val1114, Val1110, and Lys1067, which are also key residues for the hydrophobic interactions between E7107 and SF3B1 ([Figure S4](#mmc1){ref-type="supplementary-material"}B). In addition, the overexpression of SF3B1 attenuated the nuclear accumulation of poly(A)^+^ RNA induced by the apigenin- and luteolin-treatment ([Figure S4](#mmc1){ref-type="supplementary-material"}C). These results provide evidence that SF3B1 is one of the cellular targets for apigenin and luteolin and plays a crucial role in the modulation of mRNA splicing by these flavonoids.

Taking these findings together, apigenin and luteolin bind to spliceosome components, and in the cells treated with these compounds, changes in the splicing of at least some mRNAs can be effectively induced, whereas the splicing of other mRNAs, such as the *β-globin* mRNA reporter, is less influenced. These findings imply that apigenin and luteolin affect the splicing of a subset of introns, rather than generally inhibiting splicing reactions.

Apigenin and Luteolin Treatment Causes Numerous Alternative Splicing Events {#sec2.3}
---------------------------------------------------------------------------

To elucidate the effect of these flavonoids on mRNA splicing, we compared the poly(A)^+^ RNA profile in flavonoid-treated cells with that in control cells using RNA-seq. Poly(A)^+^ RNA was purified from total RNAs derived from either control cells or flavonoid-treated cells. RNA-seq reads were mapped with STAR ([@bib6]) against the hg38 human genome and to the obtained mapping data; we applied rMATS, a bioinformatic tool, to detect alternative splicing events ([Figure 4](#fig4){ref-type="fig"}A) ([@bib43]). We detected a wide variety of alternative splicing events induced by treatment with either flavonoid ([Figures 4](#fig4){ref-type="fig"}B and 4C). Among the altered splicing patterns, retained intron (RI) was the most frequently detected, followed by skipped exon (SE). Since apigenin and luteolin have similar structures and binding proteins, we hypothesized that they commonly regulate mRNA splicing. To investigate the regulatory mechanism involved, we focused on their common events ([Figures 4](#fig4){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}). Specifically, we performed gene ontology analysis on the events overlapping between apigenin- and luteolin-treated cells ([Figures 4](#fig4){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}), indicating that the mRNAs with the retention of introns due to these flavonoids are particularly associated with RNA processing, mRNA metabolic process, and mRNA splicing. RT-PCR using cDNA generated from total RNA successfully confirmed some of the apigenin- and luteolin-derived RIs and another alternative splicing event identified in our rMATS analysis, whereas neither tricetin nor naringenin induced these changes. This demonstrated the significance of the specific structure within these flavonoids for their ability to exert such activity ([Figures 4](#fig4){ref-type="fig"}F and [S6](#mmc1){ref-type="supplementary-material"}). Previous studies suggested that unspliced mRNAs are inefficiently exported to the cytoplasm, leading to poly(A)^+^ RNA accumulation in nuclear speckles ([@bib19], [@bib20]). Based on these findings, we hypothesized that a phenotype derived from apigenin and luteolin treatment, namely, the nuclear speckle-associated poly(A)^+^ RNA accumulation, reflects nuclear-retained mRNAs with introns. Therefore, we focused on the RIs for further investigation.Figure 4Global Analysis of mRNA Splicing Affected by Apigenin and Luteolin(A) Alternative splicing analysis scheme. Cells were treated with DMSO, apigenin (75 μM), or luteolin (75 μM) for 24 h; then, total RNA was extracted from the cells. Next, poly(A)^+^ RNA was purified and fragmented for RNA sequencing. Alternative splicing analysis was performed using rMATS.(B) Alternative splicing analysis revealed five alternative splicing patterns that were output by rMATS. Upper row indicates the numbers of total splicing events detected in each alternative splicing pattern; bottom row indicates the numbers of statistically significant (false discovery rate: FDR \<0.05) splicing pattern changes upon apigenin (blue) or luteolin treatment (green).(C) Frequency of splicing pattern changes by apigenin or luteolin relative to the total splicing events is calculated using the data in (B).(D) Venn diagram shows the numbers of apigenin- or luteolin-induced retained intron events.(E) Gene ontology analysis of apigenin- and luteolin-induced retained intron events. Common target genes of apigenin and luteolin (the number shown in bold in [Figure 4](#fig4){ref-type="fig"}D) were uploaded to the DAVID database for GO analysis. Apigenin- and luteolin-targeted genes in U2OS cells were enriched for several GO terms categorized in "Biological Process." Ten GO terms are listed in order of their p values. The "Count" column denominator indicates the number of genes assigned a DAVID ID among the uploaded target genes of apigenin and luteolin in retained intron events. The numerator indicates the number of genes associated with each GO term.(F) Validation of retained introns regulated by apigenin and luteolin. In the upper panels, IGV snapshots of retained introns induced by apigenin (blue) and luteolin (green) are shown. Gene structure is depicted at the bottom of each snapshot, with horizontal lines indicating introns and boxes indicating exons. Red square lines surrounding introns indicate regions affected by apigenin and luteolin. Lower panels: RT-PCR was performed using total RNA samples to detect apigenin- or luteolin-induced retained introns. Representative results of triplicate experiments are shown. DNA size in base pairs (b.p.) is indicated on the left side. RT: reverse transcription. M: DNA size marker.See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

Apigenin- and Luteolin-Induced Alternative Splicing Leads to a Change in Gene Expression {#sec2.4}
----------------------------------------------------------------------------------------

Taking into account the possibility that mRNAs with RIs are less effectively exported to the cytoplasm, it was assumed that the expression of genes with apigenin- and luteolin-sensitive introns decreases upon treatment with these flavonoids. To test this hypothesis, we fractionated the cytoplasmic RNA ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Our RT-PCR analysis clearly detected RIs caused by the treatment with these flavonoids in the whole-cell fractions, but not in the cytoplasmic fractions, indicating that mRNAs harboring those introns are not exported to and/or eliminated in the cytoplasm ([Figure 5](#fig5){ref-type="fig"}A). A significant decrease in the expression of genes whose splicing is inhibited by apigenin and luteolin treatment was demonstrated for the matured mRNAs in the cytoplasm ([Figure 5](#fig5){ref-type="fig"}A), as well as at the protein level (ANKZF1, PSMA1, and ZWINT) ([Figure S7](#mmc1){ref-type="supplementary-material"}B). In contrast, SEs triggered by apigenin and luteolin treatment were efficiently detected in either fraction ([Figure S7](#mmc1){ref-type="supplementary-material"}C), indicating that these mRNAs associated with exon skipping are efficiently exported to the cytoplasm. Neither the splicing nor the cytoplasmic expression level of nontarget introns appeared to be affected following treatment with apigenin and luteolin.Figure 5The Expression Level of Retained Intron-Containing mRNA in the Cytoplasm(A) Detection of retained intron events in the cytoplasm after apigenin and luteolin treatment. RT-PCR was performed using total RNA and cytoplasmic RNA. DNA size in base pairs (b.p.) is indicated on the left side. Non-targeted introns that are not regulated by apigenin and luteolin are shown at the bottom of (A). Representative results of triplicate experiments are shown. To compare the mRNA expression in cytoplasmic fractions, RT-qPCR was performed using cytoplasmic RNA. Values represent the relative expression of the indicated mRNA normalized to *TBP*. Each value is mean ± SD of three independent experiments. Statistical analysis was performed using one-way ANOVA followed by Dunnett\'s test. \*\*\*p \< 0.001, n.s.: not significant.(B) The effect of nonsense-mediated decay (NMD) on mRNA with retained intron in the cytoplasmic fraction was examined. Cycloheximide (CHX) was used as an NMD inhibitor. U2OS cells were treated with CHX (50 μg/mL) in the presence of apigenin (75 μM) or luteolin (75 μM) for 24 h. RT-PCR products of variant transcripts were detected. The digit panels below the photo shows the percentage of unspliced mRNA band intensity and representative results of triplicate experiments. Blue circle indicates a reference stop codon, and red circle indicates a premature termination codon (PTC). PTC + means that the transcript variant has PTC. *SRSF2*, a well-known target of NMD, was used as a positive control ([@bib9]). Dotted region in the *SRSF2* figure indicates protein-coding sequence, and primer locations (black arrows) are marked on the *SRSF2* gene.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Intron retention often produces premature termination codon (PTC) that makes the associated coding mRNAs sensitive to nonsense-mediated mRNA decay (NMD) in the cytoplasm ([@bib13]). Indeed, we found PTCs within apigenin- and luteolin-derived unspliced mRNAs ([Figure 5](#fig5){ref-type="fig"}B). The absence of these unspliced mRNAs in the cytoplasm might be explained by the intense susceptibility of these RNAs to NMD, besides the retention of RNAs within the nucleus. To discriminate between these two possibilities, an NMD assay was performed ([Figure 5](#fig5){ref-type="fig"}B). In the cytoplasmic fraction, a PTC-containing transcript variant of *SRSF2*, a well-known NMD target ([@bib9]), was detected only in the presence of cycloheximide (CHX), an NMD inhibitor, demonstrating disturbed NMD under these conditions. In contrast, unspliced mRNAs caused by apigenin and luteolin were not detected irrespective of the integrity of NMD, indicating that apigenin- and luteolin-elicited unspliced mRNAs are eliminated from the cytoplasm mainly by their nuclear retention, rather than by the digestion in the cytoplasm.

Taking these findings together, as a consequence of various alternative splicing events, such as the nuclear retention of unspliced mRNAs and the expression of exon skipping-caused transcript variants, these flavonoids induce a change in the cytoplasmic transcriptome.

Apigenin and Luteolin Inhibit Splicing of Introns with Weak Splice Sites {#sec2.5}
------------------------------------------------------------------------

To characterize introns whose splicing is affected by apigenin and luteolin, we compared their intron length, GC content, splice site score, and BPS score with those of all of the introns annotated in the human genome ([Figure 6](#fig6){ref-type="fig"}A). Splice site score was calculated using MaxEntScan ([@bib51]). The BPS score was calculated using the SVM-BP program ([@bib4]). The results suggested that RIs caused by apigenin and luteolin treatment are shorter, have weaker 5′ and 3′ splice sites, and show higher GC content, whereas the BPS scores are similar between these flavonoid-target and nontarget introns.Figure 6Apigenin and Luteolin Induce Intron Retention with Weak Splice Sites(A) The bioinformatic analysis on retained introns induced by apigenin and luteolin. All introns of human reference genes and retained introns induced by apigenin and luteolin were analyzed. Boxes show median (center line) and upper and lower quartile ranges. Whiskers show the lowest and highest values. Statistical analysis was performed using the two-sided Mann--Whitney *U* test. \*p \< 0.05, \*\*\*p \< 0.001, n.s.: not significant.(B and C) Upper left panels in (B and C) present schematic representations of mini gene constructs affected by apigenin and luteolin. The CMV promoter and BGH poly(A) sites are shown. Jagged line in the figure of the exon indicates that the edges of the exons have been partially deleted in order to distinguish endogenous mRNA from transgene-derived mRNA. The mutated nucleotides in each mutated-mini gene construct are shown in red, and the exon sequence is shown in upper case. Splice site score (ss score) was calculated using MaxEntScan. Lower left panels in (B and C) present schematic representations of the endogenous gene. The locations of the primers that amplify the endogenous target are marked in the schematic representation of the endogenous gene (black arrows). Right panels in (B and C) show the results of RT-PCR. DNA size in base pairs (b.p.) is indicated on the left side. The mRNAs derived from the transgene are shown in the upper right panels, and endogenous mRNAs are shown in the lower right panels. The digit panels below the photo show the percentage of unspliced mRNA band intensity and representative results of triplicate experiments.See also [Figure S8](#mmc1){ref-type="supplementary-material"}.

To confirm the significance of weak splice sites for the susceptibility to these flavonoids, sequences of 5′ and 3′ splice sites within introns of interest were manipulated to display a higher splice site score, and it was examined whether the splicing of these engineered introns is still sensitive to apigenin and luteolin. For this purpose, introns accompanied by portions of both neighboring exons were cloned into an expression vector, and these vectors were transiently transfected into U2OS cells, achieving the expression of these reporter RNAs under the control of the CMV promoter. We successfully obtained several mini genes, *PLXNB1*, *PSMA1*, and *ANKZF1*, which can efficiently reproduce apigenin- and luteolin-induced intron retention exhibited by the endogenous genes ([Figure 5](#fig5){ref-type="fig"}A). Mutating the splice sites of the introns in these mini genes to raise the splice sites with a higher score, namely, changes of 1.11→6.99 or 1.11→9.46 in the 3′ splice site score (3′ ss score) of the *PLXNB1* mini gene, −5.12→9.07 in the 5′ splice site score (5′ ss score), −9.15→9.66 in the 3′ ss score in the *PSMA1* mini gene, and −0.11→10.45 in the 5′ ss score in the *ANKZF1* mini gene, almost abolished their responses to apigenin and luteolin ([Figures 6](#fig6){ref-type="fig"}B, 6C, and [S8](#mmc1){ref-type="supplementary-material"}). In addition, the *PLXNB1* mini gene with its 3′ ss mutated to achieve a moderate score of 6.99 still exhibited subtle susceptibility to these flavonoids. The efficiencies of either apigenin or luteolin treatment in these experiments were confirmed by RT-PCR analysis of the endogenous mRNAs from the same samples transiently expressing each reporter mini gene ([Figures 6](#fig6){ref-type="fig"}B, 6C, and [S8](#mmc1){ref-type="supplementary-material"}). And as mentioned above, the *β-globin* reporter indicated that its transcript escaped from flavonoid-induced splicing inhibition ([Figures 3](#fig3){ref-type="fig"}B and 3C). These findings suggest that weak splice sites are crucial for an intron\'s susceptibility to apigenin and luteolin.

Apigenin- and Luteolin-Derived Unspliced mRNAs Accumulate at Nuclear Speckles {#sec2.6}
-----------------------------------------------------------------------------

Next, we assessed the subcellular localization of these mini gene-derived mRNAs in the presence or absence of apigenin and luteolin to examine whether the nuclear accumulation of bulk poly(A)^+^ RNAs observed in the flavonoid-treated cells contains the flavonoid-caused unspliced mRNAs. To visualize these reporter mRNAs, a sequence complementary to the *β-globin* FISH probe used as shown in [Figure 3](#fig3){ref-type="fig"}A was inserted into either the *PLXNB1* or *PSMA1* mini gene. RT-PCR analysis demonstrated that *β-globin* sequence-fused mini genes maintained their response to the flavonoids ([Figure 7](#fig7){ref-type="fig"}A). The results also showed that mutating the splice sites to have a higher score abolished their response to the flavonoids, as observed with native sequence reporters ([Figures 6](#fig6){ref-type="fig"}B, 6C, and [7](#fig7){ref-type="fig"}A). In either apigenin-/luteolin-treated or untreated cells, these mini genes were transiently expressed and visualized by FISH using *β-globin* probe ([Figure 7](#fig7){ref-type="fig"}B). Bulk poly(A)^+^ RNA was simultaneously visualized in the same cells to verify the effect of the treatment with flavonoids. In DMSO-treated cells, expressed reporter mRNAs were efficiently exported to the cytoplasm. In apigenin- and luteolin-treated cells, WT reporter mRNAs were diminished from the cytoplasm and accumulated in the nucleus, whereas apigenin- and luteolin-insensitive mutated mRNAs were efficiently exported to the cytoplasm under these conditions. Notably, in the flavonoid-treated nucleus, WT mRNA reporters co-localized with bulk poly(A)^+^ RNAs, indicating that flavonoid-caused unspliced reporter mRNAs accumulate at the nuclear speckles.Figure 7Localization of mRNAs with Retained Intron Induced by Apigenin and Luteolin(A) Schematic of mini gene constructs with *β-globin* FISH probe tag. The CMV promoter and BGH poly(A) sites are shown. DNA size in base pairs (b.p.) is indicated on the left side. The digit panels below the photo show the percentage of unspliced mRNA band intensity and representative results of triplicate experiments.(B) The localization of target mRNA was observed. Bulk poly(A)^+^ RNA (green), target mRNA (red), and chromosomal DNA (blue) were visualized in U2OS cells. Scale bar, 10 μm.

Tumorigenic Cells Exhibit More Prominent Sensitivity to Apigenin and Luteolin than Non-tumorigenic Cells {#sec2.7}
--------------------------------------------------------------------------------------------------------

It has been shown that cancer cells are more sensitive to reagents inhibiting splicing (see [Discussion](#sec3){ref-type="sec"}) ([@bib7]). We thus assessed whether this is also the case with apigenin and luteolin by comparing their effects on U2OS, HeLa, and MCF7 tumorigenic cell lines with those on non-tumorigenic HaCaT cells. When added at 75 μM, apigenin and luteolin caused prominent nuclear poly(A)^+^ RNA accumulation in all of the tumorigenic cell lines tested, whereas the nuclear poly(A)^+^ RNA accumulation in HaCaT cells under the same conditions was moderate ([Figure 8](#fig8){ref-type="fig"}A). In addition, tumorigenic cells exhibited a steeper dose response than HaCaT cells.Figure 8Inhibition of mRNA Processing and Proliferation of Tumorigenic Cells by Apigenin and Luteolin(A) Bulk poly(A)^+^ RNA (red) and chromosomal DNA (blue) were visualized in HeLa, MCF7, and HaCaT cells. Cells were treated with the indicated concentrations of each compound for 24 h. Scale bar, 50 μm. In lower panels, the signal intensities of bulk poly(A)^+^ RNA in the whole cell and in the nucleus were quantified using ImageJ (n = 35). Boxes show median (center line) and upper and lower quartiles. Whiskers show the lowest and highest values. Statistical analysis was performed using one-way ANOVA followed by Dunnett\'s test. \*\*\*p \< 0.001.(B) Proliferation of U2OS and HaCaT cells treated with the indicated concentrations of each compound for 24, 48, or 72 h. Cell viability was determined by MTT assay. Cell viability in comparison with that of DMSO-treated cells, which was set to 100%, is reported as mean ± SD of six independent experiments.See also [Figure S9](#mmc1){ref-type="supplementary-material"}.

We also examined the effect of these compounds on the cell viability ([Figures 8](#fig8){ref-type="fig"}B and [S9](#mmc1){ref-type="supplementary-material"}). These flavonoids significantly inhibited the proliferation of U2OS cells in a dose- and time-dependent manner. HaCaT cells also exhibited a dose- and time-dependent response to these flavonoids but to a lesser extent than U2OS cells at all doses and time points. Other non-tumorigenic cells, WI-38 and TIG-1, also gave similar results with HaCaT cells. Taken together, apigenin and luteolin seem to be more effective for tumorigenic cells than for non-tumorigenic cells ([Figure S9](#mmc1){ref-type="supplementary-material"}).

Discussion {#sec3}
==========

Food not only provides nutrition, taste, and texture but also regulates biological function. The daily intake of bioactive food compounds is expected to be effective for the prevention of chronic diseases. For example, polyphenols and carotenoids have antioxidant activity and function in preventing lifestyle-related diseases ([@bib36], [@bib38], [@bib54]). Flavonoids, which are abundant in fruit and vegetables, have been reported to reduce the risk of lifestyle-related diseases and carcinogenesis ([@bib2], [@bib28]). Despite the broad bioactivity of flavonoids, few studies on their regulatory activity against mRNA processing, especially splicing, have been reported. We previously searched for compounds derived from food that have the ability to inhibit mRNA processing and identified such effects in compounds with a flavone skeleton ([@bib23], [@bib24]).

In this study, we have shown that, among the flavonoids, apigenin and luteolin have remarkable activity of inhibiting mRNA processing. Several lines of evidence indicate that this activity is derived from the direct inhibition of splicing. Our rMATS analysis demonstrated that all types of alternative splicing events are provoked by treatment with apigenin and luteolin, and the retention of introns is the event having the highest frequency. It was previously shown that splicing inhibition by either spliceostatin A treatment or the knockdown of a component of U2 snRNP or U5 snRNP, such as SF3B1 or PRPF8, causes the retention of numerous introns in mRNAs coding RNA processing factors ([@bib49], [@bib53]), implying that these mRNAs are highly sensitive to splicing inhibition. Such enrichment of RNA processing factors, especially of mRNA splicing, was also observed in the genes that we identified to harbor introns whose retention was induced by apigenin and luteolin. It has been reported that unspliced mRNAs resulting from the global inhibition of splicing by spliceostatin A treatment manifest as a robust accumulation of bulk poly(A)^+^ RNAs at the nuclear speckles ([@bib3], [@bib20]). Similarly, we observed that apigenin and luteolin treatment induced the accumulation of bulk poly(A)^+^ RNA, as well as the retention of intron-containing transcripts from target mini genes, in the nuclear speckles, implying that these flavonoids affect a broad range of mRNA splicing events. Our results from LC-MS/MS, docking studies and SF3B1 overexpression analysis simply suggest that these flavonoids interact with U2 and U5 snRNP, possibly through the interaction with SF3B1, to modulate mRNA splicing, although we cannot exclude other possible splicing regulatory mechanisms by these flavonoids, such as SUMOylation of spliceosomal components previously reported for an apigenin- and luteolin-related biflavonoid, hinokiflavone ([@bib37]). Together, these findings suggest that apigenin and luteolin associate with spliceosomal components to directly prevent the function of spliceosomes, thus affecting alternative splicing at the genome-wide level.

Our rMATS analysis did not detect previously demonstrated alternative splicing events induced by apigenin and luteolin treatment, such as the change of splicing pattern of *Caspase-9* and *c-FLIP* mRNA ([@bib1]), although it was efficiently recapitulated by RT-PCR analysis, indicating that these flavonoids actually affect a broader range of splicing events beyond our criteria of rMATS analysis. Such events may include the very subtle splicing perturbation that, if it occurs to numerous targets, can contribute to the flavonoid-induced nuclear bulk poly(A)^+^ RNA accumulation.

Our data also illustrated a mechanism by which these flavonoids inhibit splicing. The bioinformatic analysis raises the possibility that weak splice sites are a general feature for the retention of introns caused by apigenin and luteolin. Supporting this hypothesis, manipulating the splice site score in the target introns abolished their sensitivity to these flavonoids and led them to be spliced out. Therefore, apigenin and luteolin presumably perturb the association of splicing-related factors with the weak splice sites to inhibit splicing.

We observed more sensitivity of tumorigenic cells to apigenin and luteolin than that observed for non-tumorigenic cells, both for the bulk mRNA processing and cell viability. The exact relationship between splicing and cancer progression is still unclear. However, splicing abnormality has been found to be involved in the onset and progression of various cancers ([@bib41], [@bib45]), and it has been suggested that cancers harboring mutations in splicing factors are highly susceptible to splicing inhibition ([@bib26]). For example, acute myeloid leukemia cells with *SF3B1* mutation exhibit reduced viability in the presence of a splicing inhibitor ([@bib42]). High sensitivity to splicing inhibition has also been demonstrated for cancers caused by *c-Myc* oncogene overexpression ([@bib18]). In this case, it has been suggested that massive amounts of *c-Myc*-driven pre-mRNA sequester a substantial population of spliceosomes to weaken the splicing activity available for endogenous pre-mRNAs, thus conferring on cells similar sensitivity for splicing inhibition as observed in cancer cells resulting from mutations in splicing factors. Hence, splicing inhibitors are attractive candidates for anti-cancer drugs. Indeed, splicing inhibitors such as H3B-8800 ([@bib42]) are under clinical trials for anti-cancer therapy. Because the concentrations at which apigenin and luteolin can effectively exert their splicing-inhibiting activities are much higher than those of previously identified compounds, such as spliceostatin A and H3B-8800, the employment of these flavonoids as anti-cancer drugs may not be so promising. Nonetheless, further evaluation of these flavonoids as anti-cancer drugs should be conducted. On the other hand, it has been reported that xenograft progression of human tumors was repressed by the oral administration of apigenin or luteolin into nude mice ([@bib27], [@bib44], [@bib50]) and that the daily intake of bulk flavonoids reduced carcinogenesis in humans ([@bib2], [@bib28]). These findings suggest a beneficial effect of these compounds on preventing cancer development when they are consumed in food on a daily basis for a considerable period.

Many screening systems to identify anti-cancer compounds are highly focused on finding compounds with strong activity. Therefore, compounds with moderate activity have been overlooked. Our study provides an effective strategy to discover compounds harboring moderate inhibitory activity on mRNA processing and to elucidate the mechanism underlying the disruption of mRNA processing induced by candidate compounds.

Limitations of the Study {#sec3.1}
------------------------

We have revealed the underlying mechanism that food-derived compounds apigenin and luteolin cause intron retention. Other than intron retention, we also observed various alternative splicing events induced by these flavonoids and whether an analogous molecular mechanism contributes to these events remains to be assessed.

A hypersensitivity of cancer cells to the splicing inhibition has been shown in many studies, implying our observed *in vitro* inhibition of cancer cell proliferation by apigenin and luteolin, as well as the previously demonstrated suppression of human tumor xenograft progression by apigenin-treatment in a mouse model, is derived from the inhibited splicing. However, a further investigation should be required to elucidate a direct relationship between these flavonoids\' inhibitory activity on splicing and their exhibited tumor growth suppressive effect.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

The RNA-seq data were submitted to Gene Expression Omnibus (accession number: [GSE128097](ncbi-geo:GSE128097){#intref0020}). Original imaging data have been deposited to Mendeley Data and are available at <https://doi.org/10.17632/t6r9jftdnr.1>.
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